Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...

AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...

Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...

Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...

Bristol Myers touts 7% Q3 revenue growth and admilparant progress as it faces 2028 patent cliffs for Eliquis and Opdivo.

Pfizer’s flood-damaged Gujarat cancer drug plant won’t resupply until 2028, deepening US chemotherapy shortages, ASHP said.

Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...

Eli Lil­ly once again dom­i­nat­ed rev­enue ex­pec­ta­tions, blow­ing past Wall Street’s es­ti­mates by about $2 bil­lion.

AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in oncology, cell therapy & AI.

FDA releases CRISPR medicine framework for personalized gene therapies, building on Baby KJ's case. Danaher's Kassim flags ...

HHS on Wednes­day said it will stop en­forc­ing a ban on the com­pound­ing of cer­tain pop­u­lar pep­tides used for well­ness ...

For­ma­tion Bio, an AI-fo­cused biotech that ac­quires out­side as­sets, de­vel­ops them and then hands them off, has raised ...